首页 > 最新文献

Global Medical Genetics最新文献

英文 中文
The Epigenetic Regulation of Quiescent in Stem Cells. 干细胞静息的表观遗传调控。
IF 1.7 Pub Date : 2023-11-22 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777072
Mehran Radak, Hossein Fallahi

This review article discusses the epigenetic regulation of quiescent stem cells. Quiescent stem cells are a rare population of stem cells that remain in a state of cell cycle arrest until activated to proliferate and differentiate. The molecular signature of quiescent stem cells is characterized by unique epigenetic modifications, including histone modifications and deoxyribonucleic acid (DNA) methylation. These modifications play critical roles in regulating stem cell behavior, including maintenance of quiescence, proliferation, and differentiation. The article specifically focuses on the role of histone modifications and DNA methylation in quiescent stem cells, and how these modifications can be dynamically regulated by environmental cues. The future perspectives of quiescent stem cell research are also discussed, including their potential for tissue repair and regeneration, their role in aging and age-related diseases, and their implications for cancer research. Overall, this review provides a comprehensive overview of the epigenetic regulation of quiescent stem cells and highlights the potential of this research for the development of new therapies in regenerative medicine, aging research, and cancer biology.

本文就静止干细胞的表观遗传调控作一综述。静止干细胞是一种罕见的干细胞群体,在激活增殖和分化之前保持细胞周期停滞状态。静止干细胞的分子特征是独特的表观遗传修饰,包括组蛋白修饰和脱氧核糖核酸(DNA)甲基化。这些修饰在调节干细胞行为中起关键作用,包括维持静止、增殖和分化。本文特别关注组蛋白修饰和DNA甲基化在静止干细胞中的作用,以及这些修饰如何通过环境线索动态调节。本文还讨论了静止干细胞研究的未来前景,包括它们在组织修复和再生方面的潜力,它们在衰老和年龄相关疾病中的作用,以及它们对癌症研究的影响。总的来说,本文综述了静止干细胞的表观遗传调控的全面概述,并强调了该研究在再生医学、衰老研究和癌症生物学新疗法开发方面的潜力。
{"title":"The Epigenetic Regulation of Quiescent in Stem Cells.","authors":"Mehran Radak, Hossein Fallahi","doi":"10.1055/s-0043-1777072","DOIUrl":"https://doi.org/10.1055/s-0043-1777072","url":null,"abstract":"<p><p>This review article discusses the epigenetic regulation of quiescent stem cells. Quiescent stem cells are a rare population of stem cells that remain in a state of cell cycle arrest until activated to proliferate and differentiate. The molecular signature of quiescent stem cells is characterized by unique epigenetic modifications, including histone modifications and deoxyribonucleic acid (DNA) methylation. These modifications play critical roles in regulating stem cell behavior, including maintenance of quiescence, proliferation, and differentiation. The article specifically focuses on the role of histone modifications and DNA methylation in quiescent stem cells, and how these modifications can be dynamically regulated by environmental cues. The future perspectives of quiescent stem cell research are also discussed, including their potential for tissue repair and regeneration, their role in aging and age-related diseases, and their implications for cancer research. Overall, this review provides a comprehensive overview of the epigenetic regulation of quiescent stem cells and highlights the potential of this research for the development of new therapies in regenerative medicine, aging research, and cancer biology.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review. microrna在结直肠癌信号通路中的临床意义综述
IF 1.7 Pub Date : 2023-11-22 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777094
Athanasios Michas, Vasileios Michas, Evangelos Anagnostou, Michail Galanopoulos, Maria Tolia, Nikolaos Tsoukalas

Colorectal carcinoma (colon and rectum) is currently considered among the most prevalent malignancies of Western societies. The pathogenesis and etiological mechanisms underlying colorectal cancer (CRC) development remain complex and heterogeneous. The homeostasis and function of normal human intestinal cells is highly regulated by microRNAs. Therefore, it is not surprising that mutations and inactivation of these molecules appear to be linked with progression of colorectal tumors. Recent studies have reported significant alterations of microRNA expression in adenomas and CRCs compared with adjacent normal tissues. This observed deviation has been proposed to correlate with the progression and survival of disease as well as with choice of optimal treatment and drug resistance. MicroRNAs can adopt either oncogenic or tumor-suppressive roles during regulation of pathways that drive carcinogenesis. Typically, oncogenic microRNAs termed oncomirs, target and silence endogenous tumor-suppressor genes. On the other hand, tumor-suppressive microRNAs are critical in downregulating genes associated with cell growth and malignant capabilities. By extensively evaluating robust studies, we have emphasized and distinguished a discrete set of microRNAs that can modulate tumor progression by silencing specific driver genes crucial in signaling pathways including Wnt/b-catenin, epidermal growth factor receptor, P53, mismatch repair DNA repair, and transforming-growth factor beta.

结直肠癌(结肠和直肠)目前被认为是西方社会最普遍的恶性肿瘤之一。结直肠癌(CRC)发展的发病机制和病因机制仍然是复杂和异质性的。正常人类肠道细胞的稳态和功能受microrna的高度调控。因此,这些分子的突变和失活似乎与结直肠肿瘤的进展有关也就不足为奇了。最近的研究报道了与邻近正常组织相比,腺瘤和crc中的microRNA表达有显著变化。这种观察到的偏差被认为与疾病的进展和生存以及最佳治疗和耐药性的选择有关。在驱动癌变的途径调控过程中,MicroRNAs可以发挥致癌或肿瘤抑制作用。通常,被称为oncomir的致癌小rna靶向并沉默内源性肿瘤抑制基因。另一方面,肿瘤抑制microrna对于下调与细胞生长和恶性能力相关的基因至关重要。通过广泛评估可靠的研究,我们强调并区分了一组离散的microrna,它们可以通过沉默在信号通路中至关重要的特定驱动基因来调节肿瘤进展,包括Wnt/b-连环蛋白、表皮生长因子受体、P53、错配修复DNA修复和转化生长因子β。
{"title":"The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review.","authors":"Athanasios Michas, Vasileios Michas, Evangelos Anagnostou, Michail Galanopoulos, Maria Tolia, Nikolaos Tsoukalas","doi":"10.1055/s-0043-1777094","DOIUrl":"https://doi.org/10.1055/s-0043-1777094","url":null,"abstract":"<p><p>Colorectal carcinoma (colon and rectum) is currently considered among the most prevalent malignancies of Western societies. The pathogenesis and etiological mechanisms underlying colorectal cancer (CRC) development remain complex and heterogeneous. The homeostasis and function of normal human intestinal cells is highly regulated by microRNAs. Therefore, it is not surprising that mutations and inactivation of these molecules appear to be linked with progression of colorectal tumors. Recent studies have reported significant alterations of microRNA expression in adenomas and CRCs compared with adjacent normal tissues. This observed deviation has been proposed to correlate with the progression and survival of disease as well as with choice of optimal treatment and drug resistance. MicroRNAs can adopt either oncogenic or tumor-suppressive roles during regulation of pathways that drive carcinogenesis. Typically, oncogenic microRNAs termed oncomirs, target and silence endogenous tumor-suppressor genes. On the other hand, tumor-suppressive microRNAs are critical in downregulating genes associated with cell growth and malignant capabilities. By extensively evaluating robust studies, we have emphasized and distinguished a discrete set of microRNAs that can modulate tumor progression by silencing specific driver genes crucial in signaling pathways including Wnt/b-catenin, epidermal growth factor receptor, P53, mismatch repair DNA repair, and transforming-growth factor beta.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Mimicry between Meningococcal B Factor H-Binding Protein and Human Proteins. 脑膜炎球菌B因子h结合蛋白与人蛋白的分子模拟。
IF 1.7 Pub Date : 2023-11-16 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1776985
Darja Kanduc

This study calls attention on molecular mimicry and the consequent autoimmune cross reactivity as the molecular mechanism that can cause adverse events following meningococcal B vaccination and warns against active immunizations based on entire antigen.

这项研究呼吁关注分子模仿和随之而来的自身免疫交叉反应,作为可能导致脑膜炎球菌B疫苗接种后不良事件的分子机制,并警告不要基于全抗原进行主动免疫。
{"title":"Molecular Mimicry between Meningococcal B Factor H-Binding Protein and Human Proteins.","authors":"Darja Kanduc","doi":"10.1055/s-0043-1776985","DOIUrl":"https://doi.org/10.1055/s-0043-1776985","url":null,"abstract":"<p><p>This study calls attention on molecular mimicry and the consequent autoimmune cross reactivity as the molecular mechanism that can cause adverse events following meningococcal B vaccination and warns against active immunizations based on entire antigen.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling FOXO3a and USP18 Functions in Idiopathic Pulmonary Fibrosis through Single-Cell RNA Sequencing of Mouse and Human Lungs. 通过小鼠和人肺单细胞RNA测序揭示FOXO3a和USP18在特发性肺纤维化中的功能
IF 1.7 Pub Date : 2023-11-15 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1776697
Ban Wang, Jichun Pan, Zhonghui Liu

Background  Idiopathic pulmonary fibrosis (IPF) is identified as a chronic, progressive lung disease, predominantly marked by enhanced fibroblast proliferation and excessive deposition of extracellular matrix. The intricate interactions between diverse molecular pathways in fibroblasts play a crucial role in driving the pathogenesis of IPF. Methods  This research is focused on elucidating the roles of FOXO3a, a transcription factor, and USP18, a ubiquitin-specific protease, in modulating fibroblast functionality in the context of IPF. FOXO3a is well-known for its regulatory effects on cellular responses, including apoptosis and oxidative stress, while USP18 is generally associated with protein deubiquitination. Results  Our findings highlight that FOXO3a acts as a critical regulator in controlling fibroblast activation and differentiation, illustrating its vital role in the pathology of IPF. Conversely, USP18 seems to promote fibroblast proliferation and imparts resistance to apoptosis, thereby contributing to the exacerbation of fibrotic processes. The synergistic dysregulation of both FOXO3a and USP18 in fibroblasts was found to significantly contribute to the fibrotic alterations characteristic of IPF. Conclusion  Deciphering the complex molecular interactions between FOXO3a and USP18 in fibroblasts provides a deeper understanding of IPF pathogenesis and unveils novel therapeutic avenues, offering a promising potential for not just halting but potentially reversing the progression of this debilitating disease.

特发性肺纤维化(IPF)是一种慢性进行性肺疾病,主要表现为成纤维细胞增殖增强和细胞外基质过度沉积。成纤维细胞中多种分子通路之间复杂的相互作用在IPF的发病机制中起着至关重要的作用。方法本研究的重点是阐明转录因子FOXO3a和泛素特异性蛋白酶USP18在IPF背景下调节成纤维细胞功能中的作用。FOXO3a以其对细胞反应的调控作用而闻名,包括凋亡和氧化应激,而USP18通常与蛋白质去泛素化有关。结果FOXO3a在成纤维细胞的活化和分化过程中发挥着重要的调节作用,在IPF的病理过程中发挥着重要作用。相反,USP18似乎促进成纤维细胞增殖并赋予细胞凋亡抗性,从而促进纤维化过程的加剧。研究发现,成纤维细胞中FOXO3a和USP18的协同失调显著促进了IPF的纤维化改变特征。结论:破译成纤维细胞中FOXO3a和USP18之间复杂的分子相互作用,可以更深入地了解IPF的发病机制,并揭示新的治疗途径,为阻止甚至逆转这种使人衰弱的疾病的进展提供了有希望的潜力。
{"title":"Unraveling FOXO3a and USP18 Functions in Idiopathic Pulmonary Fibrosis through Single-Cell RNA Sequencing of Mouse and Human Lungs.","authors":"Ban Wang, Jichun Pan, Zhonghui Liu","doi":"10.1055/s-0043-1776697","DOIUrl":"https://doi.org/10.1055/s-0043-1776697","url":null,"abstract":"<p><p><b>Background</b>  Idiopathic pulmonary fibrosis (IPF) is identified as a chronic, progressive lung disease, predominantly marked by enhanced fibroblast proliferation and excessive deposition of extracellular matrix. The intricate interactions between diverse molecular pathways in fibroblasts play a crucial role in driving the pathogenesis of IPF. <b>Methods</b>  This research is focused on elucidating the roles of FOXO3a, a transcription factor, and USP18, a ubiquitin-specific protease, in modulating fibroblast functionality in the context of IPF. FOXO3a is well-known for its regulatory effects on cellular responses, including apoptosis and oxidative stress, while USP18 is generally associated with protein deubiquitination. <b>Results</b>  Our findings highlight that FOXO3a acts as a critical regulator in controlling fibroblast activation and differentiation, illustrating its vital role in the pathology of IPF. Conversely, USP18 seems to promote fibroblast proliferation and imparts resistance to apoptosis, thereby contributing to the exacerbation of fibrotic processes. The synergistic dysregulation of both FOXO3a and USP18 in fibroblasts was found to significantly contribute to the fibrotic alterations characteristic of IPF. <b>Conclusion</b>  Deciphering the complex molecular interactions between FOXO3a and USP18 in fibroblasts provides a deeper understanding of IPF pathogenesis and unveils novel therapeutic avenues, offering a promising potential for not just halting but potentially reversing the progression of this debilitating disease.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Possible Role of Mitochondrial Transfer RNA Gene 5816 A > G Genetic Polymorphism (m.5816A > G) in a 3-Year-Old Child with Dystonia: Report of a Case. 线粒体转移RNA基因5816A的可能作用 > G遗传多态性(m.5816A > G) 一例3岁儿童肌张力障碍:病例报告。
IF 1.7 Pub Date : 2023-09-27 eCollection Date: 2023-09-01 DOI: 10.1055/s-0043-1774708
Sumei Wang, Minglu Liang, Jiehui Ma, Sheng Huang, Lili Fan, Feng Zhu, Dan Sun

Background  Mutations in the mitochondrial transfer RNA (mt-tRNA) gene are a hotspot for mitochondrial DNA (mtDNA) mutations and are most common in mitochondrial diseases. Methods  We identified the mt-tRNA gene 5816 A > G (m.5816 A > G) mutation in a 3-year-old child with dystonia who died. We performed clinical evaluation, genetic analysis, and biochemical investigation with mitochondrial function testing. Results  Our patient was found to have dystonia with hyperlactatemia. Electroencephalogram findings were abnormal in children with numerous multifocal spikes, multispike, spikes and slow waves, slow waves and low amplitude fast waves, more pronounced in the occipital region bilaterally, and occurring continuously during sleep. One year later, the preexisting patient had seizures lasting 1 to 2 hours and subsequently died. mtDNA sequencing revealed that the proband, her mother, and her grandmother all carried the m.5816A > G mutation. Oxygen consumption rate (OCR) assays revealed that the proband's basal resting OCR, adenosine triphosphate production, proton leak, maximal respiration, and spare capacity OCR were all significantly lower compared with healthy children of the same age. Conclusion  The present case demonstrates a childhood dystonia caused by a mt-tRNA gene 5816 A > G mutation, which has never been reported before. Our findings provide valuable new insights into the pathogenic mechanism and function of the m.5816A > G mutation.

背景 线粒体转移RNA(mt-tRNA)基因的突变是线粒体DNA(mtDNA)突变的热点,在线粒体疾病中最常见。方法 我们鉴定了mt-tRNA基因5816A > G(m.5816 A > G) 一名死于肌张力障碍的3岁儿童的突变。我们通过线粒体功能测试进行了临床评估、基因分析和生化调查。后果 我们的病人被发现有肌张力障碍伴高乳血症。儿童脑电图表现异常,有许多多灶性棘波、多棘波、棘波和慢波、慢波和低振幅快波,在双侧枕部更为明显,并在睡眠中持续发生。一年后,先前存在的患者癫痫发作持续了1到2次 数小时后死亡。mtDNA测序显示,先证者、她的母亲和她的祖母都携带m.5816A > G突变。耗氧率(OCR)测定显示,与同龄健康儿童相比,先证者的基础静息OCR、三磷酸腺苷产生、质子泄漏、最大呼吸和剩余容量OCR均显著降低。结论 本病例显示由mt-tRNA基因5816A引起的儿童肌张力障碍 > G突变,以前从未报道过。我们的发现为m.5816A的致病机制和功能提供了有价值的新见解 > G突变。
{"title":"Possible Role of Mitochondrial Transfer RNA Gene 5816 A > G Genetic Polymorphism (m.5816A > G) in a 3-Year-Old Child with Dystonia: Report of a Case.","authors":"Sumei Wang,&nbsp;Minglu Liang,&nbsp;Jiehui Ma,&nbsp;Sheng Huang,&nbsp;Lili Fan,&nbsp;Feng Zhu,&nbsp;Dan Sun","doi":"10.1055/s-0043-1774708","DOIUrl":"10.1055/s-0043-1774708","url":null,"abstract":"<p><p><b>Background</b>  Mutations in the mitochondrial transfer RNA (mt-tRNA) gene are a hotspot for mitochondrial DNA (mtDNA) mutations and are most common in mitochondrial diseases. <b>Methods</b>  We identified the mt-tRNA gene 5816 A > G (m.5816 A > G) mutation in a 3-year-old child with dystonia who died. We performed clinical evaluation, genetic analysis, and biochemical investigation with mitochondrial function testing. <b>Results</b>  Our patient was found to have dystonia with hyperlactatemia. Electroencephalogram findings were abnormal in children with numerous multifocal spikes, multispike, spikes and slow waves, slow waves and low amplitude fast waves, more pronounced in the occipital region bilaterally, and occurring continuously during sleep. One year later, the preexisting patient had seizures lasting 1 to 2 hours and subsequently died. mtDNA sequencing revealed that the proband, her mother, and her grandmother all carried the m.5816A > G mutation. Oxygen consumption rate (OCR) assays revealed that the proband's basal resting OCR, adenosine triphosphate production, proton leak, maximal respiration, and spare capacity OCR were all significantly lower compared with healthy children of the same age. <b>Conclusion</b>  The present case demonstrates a childhood dystonia caused by a mt-tRNA gene 5816 A > G mutation, which has never been reported before. Our findings provide valuable new insights into the pathogenic mechanism and function of the m.5816A > G mutation.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41104641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy. 多发性硬化症患者ADAR表达和单核苷酸变异影响对干扰素治疗的反应
IF 1.7 Pub Date : 2023-09-01 DOI: 10.1055/s-0043-1771001
Fatemeh Fakhr, Vahid Shaygannejad, Mehdi Khorrami, Leila Saberi, Omid Mirmosayyeb, Erfan Sadeghi, Majid Kheirollahi

Interferon (IFN)-β is the first-line disease management choice in multiple sclerosis (MS) with profound effects; however, in up to 50% of patients, clinical response does not occur. Ascertaining the responding state, need a long-term clinical follow-up, and this may lead to delay in use of other effective medications. IFN-induced cascade and its regulation is considered to play a major role in MS. Adenosine deaminase, RNA-specific (ADAR) dysregulation is important to IFN signaling pathway as an activity suppressor. Hence, we investigated the expression of ADAR and its single nucleotide variants of rs2229857 association with response to IFN-β in relapsing-remitting MS patients. mRNA levels and genotyping of rs2229857 in 167 MS patients were investigated via SYBR Green real-time (RT)-quantitative polymerase chain reaction and high-resolution melting RT PCR, respectively. The allele-A in rs2229857 and higher expression of ADAR were associated with poor response to IFN-β. Two response groups were significantly different in terms of annualized relapse rate, first symptoms, first extended disability status scale (EDSS), current EDSS, and the MS severity score. According to this study's findings, assessment of transcript levels and also variants in ADAR may be useful in identifying patients' response to IFN-β before starting treatment. Further investigations are needed to determine the potency of ADAR to be a predictive biomarker in drug responsiveness.

干扰素(IFN)-β是多发性硬化症(MS)的一线疾病管理选择,具有深远的影响;然而,高达50%的患者没有出现临床反应。确定反应状态,需要长期的临床随访,这可能导致其他有效药物的使用延迟。IFN诱导的级联及其调控被认为在ms中起主要作用。腺苷脱氨酶,rna特异性(ADAR)失调是IFN信号通路中重要的活性抑制因子。因此,我们在复发缓解型MS患者中研究了ADAR及其rs2229857单核苷酸变体的表达与IFN-β应答的关联。采用SYBR Green实时(RT)定量聚合酶链反应和高分辨率熔融RT - PCR检测167例MS患者rs2229857 mRNA水平和基因分型。rs2229857的等位基因a和ADAR的高表达与IFN-β的不良反应相关。两个缓解组在年复发率、首发症状、首次延长残疾状态量表(EDSS)、当前EDSS和MS严重程度评分方面存在显著差异。根据这项研究的发现,评估ADAR的转录水平和变异可能有助于在开始治疗前确定患者对IFN-β的反应。需要进一步的研究来确定ADAR作为药物反应性预测性生物标志物的效力。
{"title":"<i>ADAR</i> Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy.","authors":"Fatemeh Fakhr,&nbsp;Vahid Shaygannejad,&nbsp;Mehdi Khorrami,&nbsp;Leila Saberi,&nbsp;Omid Mirmosayyeb,&nbsp;Erfan Sadeghi,&nbsp;Majid Kheirollahi","doi":"10.1055/s-0043-1771001","DOIUrl":"https://doi.org/10.1055/s-0043-1771001","url":null,"abstract":"<p><p>Interferon (IFN)-β is the first-line disease management choice in multiple sclerosis (MS) with profound effects; however, in up to 50% of patients, clinical response does not occur. Ascertaining the responding state, need a long-term clinical follow-up, and this may lead to delay in use of other effective medications. IFN-induced cascade and its regulation is considered to play a major role in MS. Adenosine deaminase, RNA-specific (ADAR) dysregulation is important to IFN signaling pathway as an activity suppressor. Hence, we investigated the expression of <i>ADAR</i> and its single nucleotide variants of rs2229857 association with response to IFN-β in relapsing-remitting MS patients. mRNA levels and genotyping of rs2229857 in 167 MS patients were investigated via SYBR Green real-time (RT)-quantitative polymerase chain reaction and high-resolution melting RT PCR, respectively. The allele-A in rs2229857 and higher expression of <i>ADAR</i> were associated with poor response to IFN-β. Two response groups were significantly different in terms of annualized relapse rate, first symptoms, first extended disability status scale (EDSS), current EDSS, and the MS severity score. According to this study's findings, assessment of transcript levels and also variants in ADAR may be useful in identifying patients' response to IFN-β before starting treatment. Further investigations are needed to determine the potency of ADAR to be a predictive biomarker in drug responsiveness.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9941492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Diagnosis of Hemophilia A and Pathogenesis of Novel F8 Variants in Shanxi, China. 山西省A型血友病分子诊断及新型F8变异的发病机制
IF 1.7 Pub Date : 2023-09-01 DOI: 10.1055/s-0043-1774322
Xialin Zhang, Kun Chen, Sicheng Bian, Gang Wang, Xiuyu Qin, Ruijuan Zhang, Linhua Yang

The aim of this study was to perform a molecular diagnosis of hemophilia A (HA) among patients in the Shanxi Province of China. Fifty-two HA patients were tested, including IVS22 (31 samples), IVS1 (3 samples), missense (11 samples), nonsense (3 samples), and 4 cases of frameshift (2 cases of deletion, 1 case of insertion, 1 case of single-base duplication). With the exception of the single-base G duplication variant (p.Ile1213Asnfs*28), this was the hotspot variant reported by research groups at an early stage. The remaining variants were found, for the first time, in the region. The missense variants p.Cys172Ser, p.Tyr404Ser, p.Asp1903Gly, and p.Ser2284Asn, the deletion variant p.Leu2249fs*9, and the insertion variant p.Pro2319fs*97 were novel variants. The application of next-generation sequencing (NGS) molecular diagnosis enriched the variant spectrum of HA, which is greatly significant for individualized genetic counseling, clinical diagnosis, and treatment. NGS and a variety of bioinformatics prediction methods can further analyze the impact of genetic variation on protein structure or function and lay the foundation to reveal the molecular pathogenic mechanism of novel variants.

本研究的目的是在中国山西省的患者中进行血友病a (HA)的分子诊断。对52例HA患者进行检测,包括IVS22(31例)、IVS1(3例)、错义(11例)、无义(3例)和移码4例(2例缺失、1例插入、1例单碱基重复)。除了单碱基G重复变异(p.i ile1213asnfs *28)外,这是研究小组早期报道的热点变异。其余的变异是首次在该地区发现的。p.Cys172Ser、p.Tyr404Ser、p.Asp1903Gly、p.Ser2284Asn错义变体、p.Leu2249fs*9、p.Pro2319fs*97为新变体。新一代测序(NGS)分子诊断的应用丰富了HA的变异谱,对个体化遗传咨询、临床诊断和治疗具有重要意义。NGS和多种生物信息学预测方法可以进一步分析遗传变异对蛋白质结构或功能的影响,为揭示新变异的分子致病机制奠定基础。
{"title":"Molecular Diagnosis of Hemophilia A and Pathogenesis of Novel F8 Variants in Shanxi, China.","authors":"Xialin Zhang,&nbsp;Kun Chen,&nbsp;Sicheng Bian,&nbsp;Gang Wang,&nbsp;Xiuyu Qin,&nbsp;Ruijuan Zhang,&nbsp;Linhua Yang","doi":"10.1055/s-0043-1774322","DOIUrl":"https://doi.org/10.1055/s-0043-1774322","url":null,"abstract":"<p><p>The aim of this study was to perform a molecular diagnosis of hemophilia A (HA) among patients in the Shanxi Province of China. Fifty-two HA patients were tested, including IVS22 (31 samples), IVS1 (3 samples), missense (11 samples), nonsense (3 samples), and 4 cases of frameshift (2 cases of deletion, 1 case of insertion, 1 case of single-base duplication). With the exception of the single-base G duplication variant (p.Ile1213Asnfs*28), this was the hotspot variant reported by research groups at an early stage. The remaining variants were found, for the first time, in the region. The missense variants p.Cys172Ser, p.Tyr404Ser, p.Asp1903Gly, and p.Ser2284Asn, the deletion variant p.Leu2249fs*9, and the insertion variant p.Pro2319fs*97 were novel variants. The application of next-generation sequencing (NGS) molecular diagnosis enriched the variant spectrum of HA, which is greatly significant for individualized genetic counseling, clinical diagnosis, and treatment. NGS and a variety of bioinformatics prediction methods can further analyze the impact of genetic variation on protein structure or function and lay the foundation to reveal the molecular pathogenic mechanism of novel variants.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shared Genes and Molecular Mechanisms between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Established by WGCNA Analysis. WGCNA分析证实非酒精性脂肪肝与肝细胞癌的基因共享及分子机制
IF 1.7 Pub Date : 2023-09-01 DOI: 10.1055/s-0043-1768957
Juan He, Xin Zhang, Xi Chen, Zongyao Xu, Xiaoqi Chen, Jiangyan Xu

Background  Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer worldwide. The histopathological features, risk factors, and prognosis of HCC caused by nonalcoholic fatty liver disease (NAFLD) appear to be significantly different from those of HCC caused by other etiologies of liver disease. Objective  This article explores the shared gene and molecular mechanism between NAFLD and HCC through bioinformatics technologies such as weighted gene co-expression network analysis (WGCNA), so as to provide a reference for comprehensive understanding and treatment of HCC caused by NAFLD. Methods  NAFLD complementary deoxyribonucleic acid microarrays (GSE185051) from the Gene Expression Omnibus database and HCC ribonucleic acid (RNA)-sequencing data (RNA-seq data) from The Cancer Genome Atlas database were used to analyze the differentially expressed genes (DEGs) between NAFLD and HCC. Then, the clinical traits and DEGs in the two disease data sets were analyzed by WGCNA to obtain W-DEGs, and cross-W-DEGs were obtained by their intersection. We performed subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) enrichment analyses of the cross-W-DEGs and established protein-protein interaction networks. Then, we identified the hub genes in them by Cytoscape and screened out the final candidate genes. Finally, we validated candidate genes by gene expression, survival, and immunohistochemical analyses. Results  The GO analysis of 79 cross-W-DEGs showed they were related mainly to RNA polymerase II (RNAP II) and its upstream transcription factors. KEGG analysis revealed that they were enriched predominantly in inflammation-related pathways (tumor necrosis factor and interleukin-17). Four candidate genes (JUNB, DUSP1, NR4A1, and FOSB) were finally screened out from the cross-W-DEGs. Conclusion  JUNB, DUSP1, NR4A1, and FOSB inhibit NAFLD and HCC development and progression. Thus, they can serve as potential useful biomarkers for predicting and treating NAFLD progression to HCC.

肝细胞癌(HCC)是世界范围内癌症死亡的主要原因之一。非酒精性脂肪性肝病(NAFLD)引起的HCC的组织病理学特征、危险因素和预后与其他肝病病因引起的HCC明显不同。目的通过加权基因共表达网络分析(weighted gene co-expression network analysis, WGCNA)等生物信息学技术探讨NAFLD与HCC之间的共享基因和分子机制,为全面认识和治疗NAFLD所致HCC提供参考。方法采用来自基因表达图谱数据库的NAFLD互补脱氧核糖核酸微阵列(GSE185051)和来自癌症基因组图谱数据库的HCC核糖核酸(RNA)测序数据(RNA-seq数据)分析NAFLD与HCC之间的差异表达基因(DEGs)。然后,通过WGCNA对两种疾病数据集中的临床特征和deg进行分析,得到w - deg,并通过它们的交集得到交叉w - deg。我们对交叉w - degs进行了基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析,并建立了蛋白质-蛋白质相互作用网络。然后利用Cytoscape对其中心基因进行鉴定,筛选出最终候选基因。最后,我们通过基因表达、存活和免疫组织化学分析验证候选基因。结果79个交叉w - deg的氧化石墨烯分析显示,它们主要与RNA聚合酶II (RNAP II)及其上游转录因子相关。KEGG分析显示,它们主要富集于炎症相关通路(肿瘤坏死因子和白细胞介素-17)。最终从交叉w - deg中筛选出4个候选基因JUNB、DUSP1、NR4A1和FOSB。结论JUNB、DUSP1、NR4A1和FOSB抑制NAFLD和HCC的发生发展。因此,它们可以作为预测和治疗NAFLD进展为HCC的潜在有用的生物标志物。
{"title":"Shared Genes and Molecular Mechanisms between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Established by WGCNA Analysis.","authors":"Juan He,&nbsp;Xin Zhang,&nbsp;Xi Chen,&nbsp;Zongyao Xu,&nbsp;Xiaoqi Chen,&nbsp;Jiangyan Xu","doi":"10.1055/s-0043-1768957","DOIUrl":"https://doi.org/10.1055/s-0043-1768957","url":null,"abstract":"<p><p><b>Background</b>  Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer worldwide. The histopathological features, risk factors, and prognosis of HCC caused by nonalcoholic fatty liver disease (NAFLD) appear to be significantly different from those of HCC caused by other etiologies of liver disease. <b>Objective</b>  This article explores the shared gene and molecular mechanism between NAFLD and HCC through bioinformatics technologies such as weighted gene co-expression network analysis (WGCNA), so as to provide a reference for comprehensive understanding and treatment of HCC caused by NAFLD. <b>Methods</b>  NAFLD complementary deoxyribonucleic acid microarrays (GSE185051) from the Gene Expression Omnibus database and HCC ribonucleic acid (RNA)-sequencing data (RNA-seq data) from The Cancer Genome Atlas database were used to analyze the differentially expressed genes (DEGs) between NAFLD and HCC. Then, the clinical traits and DEGs in the two disease data sets were analyzed by WGCNA to obtain W-DEGs, and cross-W-DEGs were obtained by their intersection. We performed subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) enrichment analyses of the cross-W-DEGs and established protein-protein interaction networks. Then, we identified the hub genes in them by Cytoscape and screened out the final candidate genes. Finally, we validated candidate genes by gene expression, survival, and immunohistochemical analyses. <b>Results</b>  The GO analysis of 79 cross-W-DEGs showed they were related mainly to RNA polymerase II (RNAP II) and its upstream transcription factors. KEGG analysis revealed that they were enriched predominantly in inflammation-related pathways (tumor necrosis factor and interleukin-17). Four candidate genes (JUNB, DUSP1, NR4A1, and FOSB) were finally screened out from the cross-W-DEGs. <b>Conclusion</b>  JUNB, DUSP1, NR4A1, and FOSB inhibit NAFLD and HCC development and progression. Thus, they can serve as potential useful biomarkers for predicting and treating NAFLD progression to HCC.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9887021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VEXAS Syndrome-Review. VEXAS Syndrome-Review。
IF 1.7 Pub Date : 2023-09-01 DOI: 10.1055/s-0043-1770958
Yue Zhang, Xifeng Dong, Huaquan Wang

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined refractory adult-onset autoinflammatory syndrome caused by somatic mutations in the ubiquitin-like modifier-activating enzyme 1 (UBA1) gene in hematopoietic stem and progenitor cells, resulting in a shift in UBA1 isoform expression. Thus, patients develop a spectrum of systemic inflammatory manifestations and hematologic symptoms. To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been established. Given the high mortality rate, VEXAS syndrome needs to be taken seriously by physicians in all specialties. This article aims to describe the key features, pathogenesis, and clinical manifestations of VEXAS syndrome to better understand the targeted treatment and improve the prognosis of VEXAS syndrome.

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic)综合征是一种新定义的成人期难治性自身炎症综合征,由造血干细胞和祖细胞中泛素样修饰物激活酶1 (UBA1)基因的体细胞突变导致UBA1亚型表达的改变而引起。因此,患者会出现一系列全身炎症表现和血液学症状。迄今为止,除了大剂量糖皮质激素外,患者对免疫抑制药物的反应很差,而且没有制定治疗指南。鉴于高死亡率,所有专业的医生都需要认真对待VEXAS综合征。本文旨在阐述VEXAS综合征的主要特征、发病机制及临床表现,以便更好地了解其针对性治疗及改善预后。
{"title":"VEXAS Syndrome-Review.","authors":"Yue Zhang,&nbsp;Xifeng Dong,&nbsp;Huaquan Wang","doi":"10.1055/s-0043-1770958","DOIUrl":"https://doi.org/10.1055/s-0043-1770958","url":null,"abstract":"<p><p>VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined refractory adult-onset autoinflammatory syndrome caused by somatic mutations in the ubiquitin-like modifier-activating enzyme 1 (UBA1) gene in hematopoietic stem and progenitor cells, resulting in a shift in UBA1 isoform expression. Thus, patients develop a spectrum of systemic inflammatory manifestations and hematologic symptoms. To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been established. Given the high mortality rate, VEXAS syndrome needs to be taken seriously by physicians in all specialties. This article aims to describe the key features, pathogenesis, and clinical manifestations of VEXAS syndrome to better understand the targeted treatment and improve the prognosis of VEXAS syndrome.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9941491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of CD44 in Head and Neck Squamous Cell Carcinoma-An In-Silico Study. CD44在头颈部鳞状细胞癌中的表达-一项计算机研究。
IF 1.7 Pub Date : 2023-09-01 DOI: 10.1055/s-0043-1772459
Loganathan Kavitha, Jayaseelan Vijayashree Priyadharsini, Deepthi Kattula, Umadevi Krishna Mohan Rao, Rajabather Balaji Srikanth, Manogaran Kuzhalmozhi, Kannan Ranganathan

Introduction  CD44, a multistructural and multifunctional transmembrane glycoprotein, is a promising cancer stem cell (CSC) marker that regulates the properties of CSCs, including self-renewal, tumor initiation, and metastasis, and confers resistance to chemotherapy and radiotherapy. The aim of the present study was to evaluate the gene and protein expression of CD44 and explore its prognostic value in head and neck squamous cell carcinoma (HNSCC). Methodology  The present observational study employs computational tools for analysis. The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma dataset (520 primary HNSCC and 44 normal tissues) from the University of Alabama at Birmingham Cancer platform was used to study the association of CD44 mRNA transcript levels with various clinicopathological characteristics of HNSCC including age, gender, tumor grade, tumor stage, human papillomavirus (HPV) status, p53 mutation status, and overall survival. The CD44 protein expression in HNSCC and normal tissues was ascertained using the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium Head-and-Neck cancer dataset (108 primary HNSCC and 71 normal tissues). Results  CD44 mRNA transcript and protein expression levels were significantly higher in HNSCC tissues than in normal tissues, and high CD44 expression was correlated with poor survival. CD44 was upregulated in Stage 1 and Grade 2 HNSCC compared with other stages and grades. Overexpression of CD44 was observed in HPV-negative and TP53-positive mutant status in HNSCC. Conclusion  The pleiotropic roles of CD44 in tumorigenesis urge the need to explore its differential expression in HNSCC. The study concludes that CD44 can be a potential diagnostic and prognostic biomarker for HNSCC and offer new molecular targets for CD44-targeted therapy for cancer management.

CD44是一种多结构、多功能的跨膜糖蛋白,是一种很有前途的肿瘤干细胞(CSC)标志物,它调节CSC的特性,包括自我更新、肿瘤发生和转移,并赋予其对化疗和放疗的抗性。本研究的目的是评估CD44基因和蛋白在头颈部鳞状细胞癌(HNSCC)中的表达,并探讨其预后价值。本观察性研究采用计算工具进行分析。来自阿拉巴马大学伯明翰癌症平台的癌症基因组图谱头颈部鳞状细胞癌数据集(520例原发性HNSCC和44例正常组织)用于研究CD44 mRNA转录物水平与HNSCC各种临床病理特征(包括年龄、性别、肿瘤分级、肿瘤分期、人乳头瘤病毒(HPV)状态、p53突变状态和总生存率)的关系。CD44蛋白在HNSCC和正常组织中的表达是使用国家癌症研究所临床蛋白质组学肿瘤分析联盟头颈癌数据集(108例原发性HNSCC和71例正常组织)确定的。结果HNSCC组织中CD44 mRNA转录和蛋白表达水平明显高于正常组织,CD44高表达与生存率低相关。与其他分期和分级相比,CD44在1期和2级HNSCC中表达上调。在HNSCC中,hpv阴性和tp53阳性突变体状态下均观察到CD44过表达。结论CD44在HNSCC肿瘤发生中的多效性,值得进一步探讨其在HNSCC中的差异表达。该研究得出结论,CD44可以作为HNSCC的潜在诊断和预后生物标志物,并为CD44靶向治疗癌症提供新的分子靶点。
{"title":"Expression of CD44 in Head and Neck Squamous Cell Carcinoma-An <i>In-Silico</i> Study.","authors":"Loganathan Kavitha,&nbsp;Jayaseelan Vijayashree Priyadharsini,&nbsp;Deepthi Kattula,&nbsp;Umadevi Krishna Mohan Rao,&nbsp;Rajabather Balaji Srikanth,&nbsp;Manogaran Kuzhalmozhi,&nbsp;Kannan Ranganathan","doi":"10.1055/s-0043-1772459","DOIUrl":"https://doi.org/10.1055/s-0043-1772459","url":null,"abstract":"<p><p><b>Introduction</b>  CD44, a multistructural and multifunctional transmembrane glycoprotein, is a promising cancer stem cell (CSC) marker that regulates the properties of CSCs, including self-renewal, tumor initiation, and metastasis, and confers resistance to chemotherapy and radiotherapy. The aim of the present study was to evaluate the gene and protein expression of CD44 and explore its prognostic value in head and neck squamous cell carcinoma (HNSCC). <b>Methodology</b>  The present observational study employs computational tools for analysis. The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma dataset (520 primary HNSCC and 44 normal tissues) from the University of Alabama at Birmingham Cancer platform was used to study the association of CD44 mRNA transcript levels with various clinicopathological characteristics of HNSCC including age, gender, tumor grade, tumor stage, human papillomavirus (HPV) status, p53 mutation status, and overall survival. The CD44 protein expression in HNSCC and normal tissues was ascertained using the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium Head-and-Neck cancer dataset (108 primary HNSCC and 71 normal tissues). <b>Results</b>  CD44 mRNA transcript and protein expression levels were significantly higher in HNSCC tissues than in normal tissues, and high CD44 expression was correlated with poor survival. CD44 was upregulated in Stage 1 and Grade 2 HNSCC compared with other stages and grades. Overexpression of CD44 was observed in HPV-negative and TP53-positive mutant status in HNSCC. <b>Conclusion</b>  The pleiotropic roles of CD44 in tumorigenesis urge the need to explore its differential expression in HNSCC. The study concludes that CD44 can be a potential diagnostic and prognostic biomarker for HNSCC and offer new molecular targets for CD44-targeted therapy for cancer management.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10049986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Global Medical Genetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1